GSDMD was activated during intestinal inflammation in the model of colitis and confirmed as a negative regulator controlling cyclic GMP-AMP synthase (cGAS)-dependent inflammation. In addition, GSDMD-mediated release of IL-1β via sEVs in the pathogenesis of colitis. The gene discussed is CGAS; the disease is colitis.